Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna S.A. reported 2Q26 consolidated revenue of S/1,238 million (+9% FX-neutral), but adjusted EBITDA fell 9% FX-neutral to S/227 million and the adjusted EBITDA margin dropped to 18.4% from 22.1% amid margin pressure in Mexico/Colombia and Peru billing-related penalties. Offsetting strength came from free cash flow of S/400 million (+181% YoY) and net cash from operating activities of S/441 million (+45% YoY), driving leverage down to 3.6x net debt/adj. EBITDA. Management reaffirmed FY2026 guidance of ~12% FX-neutral revenue growth and 10%–14% adjusted EBITDA growth (expected toward the low end, excluding Peru billing-penalty impact).

Analysis

The market should treat this as a quality-of-earnings quarter, not a simple growth beat. The important split is that revenue is being pulled by higher-acuity mix and better payer terms, while EBITDA is being temporarily diluted by talent spend, billing friction, and cost resets; that can still be constructive if working-capital gains are real. The risk is that part of the cash conversion improvement comes from payables/financing and tax timing, so the equity can rerate faster than the underlying operating margin if investors over-trust headline FCF.

Competitive dynamics are improving where Auna is deepening moats: oncology, complex surgery, and insurer tiering in Mexico raise switching costs and make smaller regional operators look undercapitalized. In Colombia, the move toward risk-sharing and away from intervention-heavy payers should improve counterparty quality and reduce receivable volatility, which is a second-order positive for suppliers and lenders but a negative for rivals still dependent on slow government collections. Peru is the weak link because the issue is process discipline, not demand, and until that is closed the stock will likely trade at a discount for execution risk rather than growth.

The next catalyst window is 1-3 months: Q3 collections, confirmation that billing reconciliations are being cleaned up, and evidence that Colombia price increases offset wage and complexity costs. Over 6-18 months, the new capacity additions and asset-light expansion can create operating leverage, but only if utilization stays high enough to absorb the fixed-cost base. The contrarian view is that consensus may be too pessimistic on EBITDA and too optimistic on cash flow; if DSO improvement and supply-chain financing are durable, leverage can compress toward the 3x target, but if those benefits fade the stock should de-rate back to a low-confidence multiple.

Key Decisions for Investors

• No immediate chase after the print; wait 1-2 weeks for post-earnings digestion and only add AUNA on weakness if the stock holds above the pre-print range and management commentary on Q3 collections stays intact.
• For existing longs, hedge event risk with a 1-3 month AUNA put spread into the next operating update; the thesis breaks if Peru billing penalties reappear or Colombia margin improvement stalls.
• Treat AUNA as a conditional deleveraging story: if Q3 DSO and cash conversion remain strong, use any pullback to build a starter long with a 3-6 month horizon, targeting rerating as net debt/EBITDA trends toward 3x.
• Avoid extrapolating the free-cash-flow headline until supplier-financing balances and receivable days are disclosed more clearly; if those reverse, trim or exit before year-end.
• Watch for a cleaner long entry only after the next disclosure confirms Peru reconciliations are closed and Colombia price increases are flowing through; if that happens, the stock has room to outperform as an operational turnaround name rather than a pure top-line story.